BACKGROUND AND PURPOSE: The κ opioid receptor antagonists demonstrate potential for maintaining abstinence from psychostimulant abuse, but existing non-peptide κ-receptor selective antagonists show exceptionally long activity. We hypothesized that the L- and D-Trp isomers of CJ-15,208, a natural cyclic tetrapeptide reported to be a κ-receptor antagonist in vitro, would demonstrate short-acting, dose-dependent antagonism in vivo, preventing reinstatement of cocaine-seeking behaviour. EXPERIMENTAL APPROACH: Affinity, selectivity and efficacy of the L-Trp and D-Trp isomers for opioid receptors were assessed in vitro in radioligand and GTPγS binding assays. Opioid receptor agonist and antagonist activities were characterized in vivo following i.c.v. administration with the 55°C warm water tail-withdrawal assay. The D-Trp isomer, which demonstrated primarily κ-receptor selective antagonist activity, was further evaluated for its prevention of stress- and drug-induced reinstatement of extinguished cocaine conditioned place preference (CPP). KEY RESULTS: The two isomers showed similar affinity and selectivity for κ receptors (K(i) 30-35 nM) as well as κ receptor antagonism in vitro. As expected, the D-Trp cyclic tetrapeptide exhibited minimal agonist activity and induced dose-dependent κ-receptor selective antagonism lasting less than 18 h in vivo. Pretreatment with this peptide prevented stress-, but not cocaine-induced, reinstatement of extinguished cocaine CPP. In contrast, the L-Trp cyclic tetrapeptide unexpectedly demonstrated mixed opioid agonist/antagonist activity. CONCLUSIONS AND IMPLICATIONS: The L-Trp and the D-Trp isomers of CJ-15,208 demonstrate stereospecific opioid activity in vivo. The relatively brief κ opioid receptor antagonism, coupled with the prevention of stress-induced reinstatement of extinguished cocaine-seeking behaviour, suggests the D-Trp isomer could be used therapeutically to maintain abstinence from psychostimulant abuse.
BACKGROUND AND PURPOSE: The κ opioid receptor antagonists demonstrate potential for maintaining abstinence from psychostimulant abuse, but existing non-peptide κ-receptor selective antagonists show exceptionally long activity. We hypothesized that the L- and D-Trp isomers of CJ-15,208, a natural cyclic tetrapeptide reported to be a κ-receptor antagonist in vitro, would demonstrate short-acting, dose-dependent antagonism in vivo, preventing reinstatement of cocaine-seeking behaviour. EXPERIMENTAL APPROACH: Affinity, selectivity and efficacy of the L-Trp and D-Trp isomers for opioid receptors were assessed in vitro in radioligand and GTPγS binding assays. Opioid receptor agonist and antagonist activities were characterized in vivo following i.c.v. administration with the 55°C warm water tail-withdrawal assay. The D-Trp isomer, which demonstrated primarily κ-receptor selective antagonist activity, was further evaluated for its prevention of stress- and drug-induced reinstatement of extinguished cocaine conditioned place preference (CPP). KEY RESULTS: The two isomers showed similar affinity and selectivity for κ receptors (K(i) 30-35 nM) as well as κ receptor antagonism in vitro. As expected, the D-Trp cyclic tetrapeptide exhibited minimal agonist activity and induced dose-dependent κ-receptor selective antagonism lasting less than 18 h in vivo. Pretreatment with this peptide prevented stress-, but not cocaine-induced, reinstatement of extinguished cocaine CPP. In contrast, the L-Trp cyclic tetrapeptide unexpectedly demonstrated mixed opioid agonist/antagonist activity. CONCLUSIONS AND IMPLICATIONS: The L-Trp and the D-Trp isomers of CJ-15,208 demonstrate stereospecific opioid activity in vivo. The relatively brief κ opioid receptor antagonism, coupled with the prevention of stress-induced reinstatement of extinguished cocaine-seeking behaviour, suggests the D-Trp isomer could be used therapeutically to maintain abstinence from psychostimulant abuse.
Authors: Nancy K Mello; Jack H Mendelson; Michelle B Sholar; Maria Jaszyna-Gasior; Nathalie Goletiani; Arthur J Siegel Journal: Neuropsychopharmacology Date: 2005-03 Impact factor: 7.853
Authors: S Arttamangkul; J E Ishmael; T F Murray; D K Grandy; G E DeLander; B L Kieffer; J V Aldrich Journal: J Med Chem Date: 1997-04-11 Impact factor: 7.446
Authors: Glenn R Valdez; Donna M Platt; James K Rowlett; Daniela Rüedi-Bettschen; Roger D Spealman Journal: J Pharmacol Exp Ther Date: 2007-08-16 Impact factor: 4.030
Authors: Jai Shankar K Yadlapalli; Benjamin M Ford; Amit Ketkar; Anqi Wan; Narasimha R Penthala; Robert L Eoff; Paul L Prather; Maxim Dobretsov; Peter A Crooks Journal: Pharmacol Res Date: 2016-09-13 Impact factor: 7.658
Authors: Abdulrahman Almatroudi; Stephen M Husbands; Christopher P Bailey; Sarah J Bailey Journal: J Psychopharmacol Date: 2015-06-04 Impact factor: 4.153
Authors: Abdulrahman Almatroudi; Mehrnoosh Ostovar; Christopher P Bailey; Stephen M Husbands; Sarah J Bailey Journal: Br J Pharmacol Date: 2017-11-06 Impact factor: 8.739
Authors: Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich Journal: Cancer Biol Ther Date: 2017-07-10 Impact factor: 4.742
Authors: Jane V Aldrich; Santosh S Kulkarni; Sanjeewa N Senadheera; Nicolette C Ross; Kate J Reilley; Shainnel O Eans; Michelle L Ganno; Thomas F Murray; Jay P McLaughlin Journal: ChemMedChem Date: 2011-07-14 Impact factor: 3.466
Authors: Ariana C Brice-Tutt; Lisa L Wilson; Shainnel O Eans; Heather M Stacy; Chloe A Simons; Grant G Simpson; Jeremy S Coleman; Michael J Ferracane; Jane V Aldrich; Jay P McLaughlin Journal: Br J Pharmacol Date: 2020-07-16 Impact factor: 8.739
Authors: J V Aldrich; S N Senadheera; N C Ross; K A Reilley; M L Ganno; S E Eans; T F Murray; J P McLaughlin Journal: Br J Pharmacol Date: 2014-07 Impact factor: 8.739
Authors: Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin Journal: J Nat Prod Date: 2013-01-17 Impact factor: 4.050
Authors: Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin Journal: Br J Pharmacol Date: 2013-05 Impact factor: 8.739
Authors: Grazyna Weltrowska; Thi M-D Nguyen; Nga N Chung; JodiAnne Wood; Xiaoyu Ma; Jason Guo; Brian C Wilkes; Yang Ge; André Laferrière; Terence J Coderre; Peter W Schiller Journal: J Med Chem Date: 2016-10-03 Impact factor: 7.446